Список проголосовавших за комментарий " Gapping up<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>OSTK</strong> +13%, <strong>ACXM</strong> +6.9%, <strong>BDN</strong> +5%, <strong>AAPL</strong> +4.7%, <strong>AMD</strong> +4.6%, <strong>AKER</strong> +4%, <strong>VNTV</strong> +3.6%, <strong>OKE</strong> +3.2%, <strong>FBHS</strong> +3.1%, (also CFO Lee Wyatt will retire)</li><li><strong>ALGN</strong> +3.1%, (also files patent infringement lawsuit against ClearCorrect and Your Smile Direct in United Kingdom), <strong>TUP</strong> +2.7%</li><li><strong>CARB</strong> +2.3%, (Carbonite acquired Double-Take Software for $65.25 mln and reports prelim Q4 results, issues FY17 guidance with Double-Take Software impact)</li><li><strong>BAX</strong> +2.3%, <strong>AVY</strong> +2.1%, <strong>X</strong> +1.6%, <strong>EQR</strong> +1.3%, <strong>USG</strong> +1.3%, <strong>ALGT</strong> +1.2%, <strong>MTSI</strong> +0.9%, <strong>ANTM</strong> +0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>OKS</strong> +28.7% (ONEOK (OKE) to acquire all of the outstanding common units of ONEOK Partners it does not already own for $9.3 bln in common stock)</li><li><strong>CERU</strong> +11.1% (announces that its Board is conducting a comprehensive review of strategic alternatives)</li><li><strong>OPHT</strong> +1.9% (initiates plan to review its strategic alternatives in order to maximize shareholder value)</li></ul><p><strong>Select Apple suppliers/related names showing strength</strong>:</p><ul><li><strong>CRUS</strong> +2.8%, <strong>SWKS</strong> +2.1%, <strong>AVGO</strong> +2.1%, <strong>MU</strong> +1%, <strong>QRVO</strong> +0.5%, <strong>QCOM</strong> +0.4%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>GALT</strong> +20.2% (says has generated sufficient financing to cover currently planned expenditures through 2017, remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December), <strong>VCEL</strong> +17.3% (announces the first implant of MACI in the US)</li><li><strong>DRYS</strong> +12.7% (DryShips confirms will release its results for the fourth quarter on February 7 after the close)</li><li><strong>XOMA</strong> +8.9% (established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery)</li><li><strong>NSTG</strong> +8.8% (announces that Humana has issued a positive coverage decision for the Prosigna Breast Cancer Gene Signature Assay)</li><li><strong>SDRL</strong> +7% (rebounding following yesterday's declines)</li><li><strong>OPXA</strong> +3.2% (further reduces workforce, terminates the employment Chief Scientific Officer)</li><li><strong>TEVA</strong> +2.3% (rebounding following yesterday's declines)</li><li><strong>MFIN</strong> +2.2% (Medallion Fincl provides long-term strategic update in ongoing transition away from medallion lending; to restructure Freshstart Venture Capital debentures, reducing Medallion exposure )</li><li><strong>PMD</strong> +2% (following late move higher after co issued press release claiming no ownership interest in Psychemedics Brasil-- still closed significantly lower)</li><li><strong>FB</strong> +1.2% (Facebook working to develop an app for TV set-top boxes, according to the WSJ )</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>IDRA</strong> +5% (assumed with a Outperform at Wedbush)</li><li><strong>MRVL</strong> +3.9% (upgraded to Buy from Sell at UBS)</li><li><strong>MRO</strong> +1.9% (upgraded to Sector Outperform from Sector Perform at Scotia)</li><li><strong>COH</strong> +1.1% (upgraded to Buy from Hold at Evercore ISI)</li><li><strong>AMGN</strong> +0.9% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>FOXA</strong> +0.8% (upgraded to Buy from Neutral at MoffettNathanson)</li></ul>"